• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research

Identification, characterization, and engineering of glycosylation in thrombolyticsa
Biotechnol Adv. 2023 May 12:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.ABSTRACTCardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modifica...
Source: Adv Data - May 14, 2023 Category: Epidemiology Authors: Martin Toul Veronika Slonkova Jan Mican Adam Urminsky Maria Tomkova Erik Sedlak David Bednar Jiri Damborsky Lenka Hernychova Zbynek Prokop Source Type: research

Venous thromboembolism in patients with idiopathic pulmonary fibrosis, based on nationwide claim data
CONCLUSION: Ischemic heart disease, ischemic stroke, and malignancy, especially lung cancer, were related to higher HR for VTE in IPF.PMID:36846942 | DOI:10.1177/17534666231155772
Source: Adv Data - February 27, 2023 Category: Epidemiology Authors: Jang Ho Lee Hoon Hee Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Jae Seung Lee Ho Cheol Kim Source Type: research

A Thrombin-Activated Peptide-Templated Nanozyme for Remedying Ischemic Stroke Via Thrombolytic and Neuroprotective Actions
This article is protected by copyright. All rights reserved.PMID:36730098 | DOI:10.1002/adma.202210144
Source: Adv Data - February 2, 2023 Category: Epidemiology Authors: Zhuoran Wang Yue Zhao Yaxin Hou Guoheng Tang Ruofei Zhang Yili Yang Xiyun Yan Kelong Fan Source Type: research

Thromboembolic events, bleeding, and mortality in patients with cerebral venous thrombosis: a nationwide cohort study
We examined the clinical course of patients with CVT overall and according to age and sex. Using Danish registries, we identified all patients with a first-time primary inpatient diagnosis of CVT from 1996 to 2018 (N = 653, median age 41 years, 67% women) and individuals from the general population, matched on age, sex, and calendar year (N = 65,300). Patients with CVT were at increased risk of venous thromboembolism (VTE) in other sites, ischemic stroke, major bleeding, and mortality. For both sexes, the increased risks of VTE in other sites were most prominent among the young (18-54 years), while the increased risks of i...
Source: Adv Data - September 16, 2022 Category: Epidemiology Authors: Nils Skajaa Jan Vandenbroucke Claus Ziegler Simonsen Henrik Toft Toft S ørensen Kasper Adelborg Source Type: research